North America Biosimilars Market Competitive
Landscape, Future Plans 2028

The North
America Biosimilars Market is expected to grow from US$ 7,115.74
million in 2022 to US$ 47,746.80 million by 2028. It is estimated to grow at a
CAGR of 37.3% from 2022 to 2028.

Driving Factors: Chronic Diseases and the North America
Biosimilars Market

The North America biosimilars market is experiencing
significant growth, driven by the escalating prevalence of chronic diseases. Factors
such as an aging population, lifestyle changes associated with urbanization,
and genetic predispositions are contributing to a surge in conditions like
diabetes, cardiovascular diseases (CVDs), and autoimmune disorders.  

• Rising
  Chronic Disease Burden:




• The
  National Council on Aging reports that 80% of adults aged 65 and over
  have at least one chronic condition, with 68% having two or more.


• The
  Centers for Disease Control and Prevention (CDC) indicates that nearly 6
  in 10 US adults have at least one chronic disease, and 4 in 10 have two
  or more.


• CVDs,
  the leading cause of global mortality according to the World Health
  Organization (WHO), account for an estimated 17.9 million deaths
  annually.   


• Diabetes
  prevalence is also on the rise. The International Diabetes
  Federation (IDF) projects that North American diabetes cases will
  increase from 46 million in 2017 to 62 million by 2045. Globally, cases
  are expected to rise from 425 million in 2017 to 629 million by 2045. 
   




• Autoimmune
  Disease and Biosimilar Use:




• Autoimmune
  diseases are increasingly affecting the population, with reports of over
  24 million Americans suffering from these conditions.


• Research
  indicates a rise in antinuclear antibodies (ANA), a key marker of
  autoimmunity, across various demographics in the US.   


• Biosimilars
  play a crucial role in treating these conditions, alongside cancers,
  kidney diseases, and diabetes.


• The
  US Food and Drug Administration (FDA) has approved numerous biosimilars,
  with a significant portion used for cancer treatments, and others for
  autoimmune and diabetic conditions.
  
  Data shows that "According to Cardinal Health, a total of 33
  biosimilars have been approved by the FDA in the US and 21 are
  commercially available. Of the 21 biosimilars on the market, 17 are used
  for treatments associated with cancers, three are used to treat
  autoimmune conditions and one is used to treat diabetes.

North America Biosimilars Market Segments Covered

North America Biosimilars Market By Disease Indication

• Cancer


• Diabetes


• Autoimmune
  Diseases


• Other
  Diseases

North America Biosimilars Market By Drug Class

• Granulocyte
  Colony-Stimulating Factors


• Human
  Growth Hormone


• Insulin


• TNF
  Blockers & Monoclonal Antibodies


• Erythropoietin-Stimulating
  Agents

North America Biosimilars Market By Route of
Administration

• Intravenous


• Subcutaneous

North America Biosimilars Market By End User

• Hospitals


• Speciality
  Clinics


• Homecare

North America Biosimilars Market Regions and Countries
Covered

North America

• US


• Canada


• Mexico

North America Biosimilars Market leaders and key company
profiles

• Amgen
  Inc


• Celltrion
  Inc


• Sanofi
  SA


• Biocon
  Ltd


• Coherus
  BioSciences Inc


• Eli
  Lilly and Co


• Sandoz
  AG


• Teva
  Pharmaceutical Industries Ltd


• Pfizer
  Inc


• Dr.
  Reddy's Laboratories Ltd

Strategic Insights for the North America Biosimilars
Market:

To navigate this dynamic market, stakeholders require
data-driven strategic insights. These insights provide:

• Comprehensive
  analysis of market trends, key players, and regional variations.


• Actionable
  recommendations for competitive differentiation and value proposition
  development.


• Utilizing
  data analytics for predictive market shift anticipation.


• A
  forward-looking perspective to ensure long-term success.

By leveraging these strategic insights, industry
participants can make informed decisions, optimize profitability, and achieve
their business objectives within the evolving North America biosimilars Market landscape.

Other Reports:

North America Small Satellite Market: https://sites.google.com/view/northamericasmallsatellitemark/home 

North America Hydrocephalus Shunts Market: https://business-news-insights.blogspot.com/2025/04/north-america-hydrocephalus-shunts.html 

North America Airway Management Devices Market: https://postyourarticle.com/north-america-airway-management-devices-market-significant-growth-technological-advancement-2028/ 

North America Ammunition Market: https://businessnews46.wordpress.com/2025/04/01/north-america-ammunition-market-trends-opportunities-by-2028/ 

About Us:

Business Market Insights is a market research platform
that provides subscription service for industry and company reports. Our
research team has extensive professional expertise in domains such as
Electronics & Semiconductor; Aerospace & Defense; Automotive &
Transportation; Energy & Power; Healthcare; Manufacturing &
Construction; Food & Beverages; Chemicals & Materials; and Technology,
Media, & Telecommunications.

Author’s Bio:

Suryakant Gadekar

Senior Market Research Expert at Business Market
Insights